Hatem Abou-Ouf1,2, Liena Zhao1, Tarek A Bismar3,4,5. 1. Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada. 2. Arnie Charbonneau Cancer Institute and Tom Baker Cancer Center, Calgary, AB, Canada. 3. Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada. Tarek.Bismar@cls.ab.ca. 4. Departments of Oncology, Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada. Tarek.Bismar@cls.ab.ca. 5. Arnie Charbonneau Cancer Institute and Tom Baker Cancer Center, Calgary, AB, Canada. Tarek.Bismar@cls.ab.ca.
Abstract
INTRODUCTION: Screening for increased levels of prostate-specific antigen (PSA) has allowed early detection of a large majority of prostate cancer (PCa) cases. However, the relative lack of specificity of PSA has resulted in significant over-diagnosis and unnecessary treatment for indolent tumors. The fusion of the transmembrane protease serine 2 with E26 transformation-specific family genes, particularly ERG, is the most widespread genetic alteration in prostate cancer, and data suggest that it is more specific for neoplastic prostate disease and may be of added prognostic value and point toward molecular subtype of PCa. METHODS: In this review, retrospective studies and clinical trials were analyzed to highlight the recent advances in our understanding of the cellular consequence of ERG rearrangement, describe its interactions with other genetic and molecular pathways, and discuss its potential diagnostic and prognostic value. CONCLUSION: ERG over-expression has an emerging role in the diagnosis of PCa pathology, although there is still debate about its prognostic value. Elucidation of the mechanisms of ERG gene rearrangements and expression promises novel therapeutic and diagnostic avenues for prostate cancer.
INTRODUCTION: Screening for increased levels of prostate-specific antigen (PSA) has allowed early detection of a large majority of prostate cancer (PCa) cases. However, the relative lack of specificity of PSA has resulted in significant over-diagnosis and unnecessary treatment for indolent tumors. The fusion of the transmembrane protease serine 2 with E26 transformation-specific family genes, particularly ERG, is the most widespread genetic alteration in prostate cancer, and data suggest that it is more specific for neoplastic prostate disease and may be of added prognostic value and point toward molecular subtype of PCa. METHODS: In this review, retrospective studies and clinical trials were analyzed to highlight the recent advances in our understanding of the cellular consequence of ERG rearrangement, describe its interactions with other genetic and molecular pathways, and discuss its potential diagnostic and prognostic value. CONCLUSION:ERG over-expression has an emerging role in the diagnosis of PCa pathology, although there is still debate about its prognostic value. Elucidation of the mechanisms of ERG gene rearrangements and expression promises novel therapeutic and diagnostic avenues for prostate cancer.
Entities:
Keywords:
Clinical implication; Diagnosis; ERG; Gene signatures; Prognosis; Prostate cancer
Authors: Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire Journal: Mod Pathol Date: 2008-05-23 Impact factor: 7.842
Authors: Katharina Grupp; Sebastian Kohl; Hüseyin Sirma; Ronald Simon; Stefan Steurer; Andreas Becker; Meike Adam; Jakob Izbicki; Guido Sauter; Sarah Minner; Thorsten Schlomm; Maria Christina Tsourlakis Journal: Mod Pathol Date: 2012-11-30 Impact factor: 7.842
Authors: Samir Al Bashir; Mohammed Alshalalfa; Samar A Hegazy; Michael Dolph; Bryan Donnelly; Tarek A Bismar Journal: J Hematol Oncol Date: 2014-03-07 Impact factor: 17.388
Authors: Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar Journal: J Cancer Res Clin Oncol Date: 2020-04-30 Impact factor: 4.553
Authors: D Ryan Ormond; B K Kleinschmidt-DeMasters; Daniel Cavalcante; Elizabeth E Smith; Scott D Cramer; M Scott Lucia Journal: J Neurooncol Date: 2019-01-17 Impact factor: 4.130
Authors: Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava Journal: Mol Cancer Res Date: 2017-06-12 Impact factor: 5.852
Authors: Andrea Bakker; Jonathan C Slack; Nalla Palanisamy; Shannon Carskadon; Sunita Ghosh; Ibrahim Khalifeh; Tarek A Bismar Journal: J Cancer Res Clin Oncol Date: 2022-08-18 Impact factor: 4.322
Authors: Tine Maj Storebjerg; Siri H Strand; Søren Høyer; Anne-Sofie Lynnerup; Michael Borre; Torben F Ørntoft; Karina D Sørensen Journal: Clin Epigenetics Date: 2018-08-07 Impact factor: 6.551